Healthcare M&A looks set to be strong again this year, following deals from Shire and Roche. But Goldman Sachs says energy's a sector to watch too.» Read More
Doing well by doing good is an elusive goal, but George Schwartz seems to have figured out how to do well by not doing things he believes are bad.
October's jobs report is expected to be one of the weakest of the year, distorted by the impact of the 16-day government shutdown.
The IRS has informed Tyco that it has disallowed roughly $2.86 billion in interest and deductions recognized by the company in its U.S. returns for 1997-2000.
Some of the names on the move ahead of the open.
Covidien President & CEO Jose Almeida discusses why now is the best time to separate the pharma business. "Covidien has been growing above market," he says.
Jim Cramer believes this company is about to create immense value with the stroke of a pen.
Cramer’s convinced the best way to for this health care company to maximize shareholder value is to break up.
The S&P 500 regained the 1,500 level for the first time in more than five years, but that's a milestone that could also trigger a pause, analysts say.
Wall Street's bull could take another run at the psychologically important 1,500 level as early as Friday, but that's a level that could also trigger a pause, analysts say.
A flood of earnings reports, including major technology and industrial companies, could make or break the stock market’s surprise January rally in the week ahead.
CNBC Contributor Barbara Ryan is taking the pulse of health care stocks at this year's "Woodstock" of health care.
Here are Wednesday's morning movers.
NEW YORK-- Goldman Sachs downgraded Johnson& Johnson, saying Tuesday that the current share price has captured all the potential for improved growth. However, Goldman analyst Jami Rubin wrote that Johnson& Johnson comes up short in the two areas she sees as likely to boost stock prices, new prescription drugs and capital allocation.
*Announces FDA 510 clearance and ce mark for Nellcor (TM) bedside. *Says new system will be available in the United States and throughout the eea. in the next few months.
NEW YORK-- Drug and medical device maker Covidien PLC said Tuesday it completed its $100 million purchase of CNS Therapeutics. Covidien announced it was buying CNS on Sept. 24. CNS is now part of Covidien's Mallinckrodt pharmaceuticals business.
Jim Cramer’s researcher, Nicole Urken, takes a look at some pockets of value creation in this unpredictable market.
Joe Almeida, Covidien president & CEO, discussed his company's strategies for growth and much more.
Few stock sectors are as reliable as drugs and health care, and astute investors know that companies such as Merck, Pfizer, and Abbott Laboratories have delivered healthy returns over the years. One stock that investors have become less enamored with, however, is Johnson & Johnson.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Every quarter hedge funds and large investors file their holdings with the SEC, revealing value picks, cyclical bets, growth opportunities and activist pushes. TheStreet.com details five stocks that hedge funds flocked to.